Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer | Zendy

Pasi A. Jänne | Zendy; Michel M. van den Heuvel | Zendy; Fabrice Barlési | Zendy; Manuel Cobo | Zendy; Julien Mazières | Zendy; Lucio Crinó | Zendy; С. В. Орлов | Zendy; Fiona Blackhall | Zendy; Juergen Wolf | Zendy; Pilar Garrido | Zendy; Artem Poltoratskiy | Zendy; G Mariani | Zendy; Dana Ghiorghiu | Zendy; Elaine Kilgour | Zendy; Paul D. Smith | Zendy; Alexander Kohlmann | Zendy; David Carlile | Zendy; David Lawrence | Zendy; Karin Bowen | Zendy; Johan Vansteenkiste | Zendy

Open Access

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

Author(s) -

Pasi A. Jänne,

Michel M. van den Heuvel,

Fabrice Barlési,

Manuel Cobo,

Julien Mazières,

Lucio Crinó,

С. В. Орлов,

Fiona Blackhall,

Juergen Wolf,

Pilar Garrido,

Artem Poltoratskiy,

G Mariani,

Dana Ghiorghiu,

Elaine Kilgour,

Paul D. Smith,

Alexander Kohlmann,

David Carlile,

David Lawrence,

Karin Bowen,

Johan Vansteenkiste

Publication year - 2017

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2017.3438

Subject(s) - medicine , docetaxel , selumetinib , oncology , kras , lung cancer , randomized controlled trial , tolerability , interquartile range , progression free survival , cancer , chemotherapy , adverse effect , colorectal cancer

There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research